International Journal of Hematology-Oncology and Stem Cell Research (Oct 2016)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes

  • Naser Mobarra,
  • Mehrnoosh Shanaki,
  • Hassan Ehteram,
  • Hajar Nasiri,
  • Mehdi Sahmani,
  • Mohsen Saeidi,
  • Mehdi Goudarzi,
  • Hoda Pourkarim,
  • Mehdi Azad

Journal volume & issue
Vol. 10, no. 4

Abstract

Read online

Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications.

Keywords